Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-064-4 | CAS number: 77-86-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable, well documented publication which meets basic scientific principles.
Data source
Reference
- Reference Type:
- publication
- Title:
- Pharmacokinetics of TRIS (hydroxymethyl-)aminomethane in the Rabbit.
- Author:
- Brasch, H. and Iven, H.
- Year:
- 1 981
- Bibliographic source:
- Arch. int. Pharmacodyn. 254:4-12
Materials and methods
- Objective of study:
- distribution
- Principles of method if other than guideline:
- Pharmocokinetics of TRIS were investigated in rabbits after a short-time infusion of a single low dose.
- GLP compliance:
- no
Test material
- Reference substance name:
- Trometamol
- EC Number:
- 201-064-4
- EC Name:
- Trometamol
- Cas Number:
- 77-86-1
- Molecular formula:
- C4H11NO3
- IUPAC Name:
- 2-amino-2-(hydroxymethyl)propane-1,3-diol
- Details on test material:
- - Analytical purity: analytical grade
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rabbit
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 3600-4400 g
Administration / exposure
- Route of administration:
- intravenous
- Vehicle:
- not specified
- Duration and frequency of treatment / exposure:
- 24 h
Doses / concentrations
- Remarks:
- Doses / Concentrations:
121 mg/kg (1 mmol/kg)
- No. of animals per sex per dose / concentration:
- 6
- Control animals:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY
- Tissues and body fluids sampled: blood
- Time and frequency of sampling: 2, 4, 8, 15 and 30 min, 1, 2, 3, 4, 6, 8, 12 and 24 h
- Method type(s) for identification: Hewlett-Packard 5710A GC equipped with a FID together with a Hewlett Packard 3380A integrator - Statistics:
- The experimental data were fitted by mulitexponential functions, using the method of least squares. The kinetic parameters of two- and three compartment models were calculated according to Gibaldi and Perrier (1975) and Wagner (1975) with a Hewlett-Packard 9820 A desk top calculator.
Results and discussion
Main ADME results
- Type:
- distribution
- Results:
- A half-life of 12.9 h was calculated. The final volume of distribution (3641 mL/kg) indicated drug accumulation inside cells, but equilibration between compartments was slow compared to drug elimination.
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- TRIS
Two min after the end of infusion the TRIS (pH 7.4) concentration in plasma was 550 µg/mL. The drug concentration then declined steadily and was only 2.9 µg/mL after 24 h. The drug exhibited three-compartment characteristics with long terminal half-life (12.9 h).
TRIS concentration in erythrocytes increased during the first hour after infusion. After 2 h drug levels in erythrocytes were about 2.5 times those in plasma and remained well above plasma levels during the rest of the observation period. This was found in all animals.
To calculate pharmacokinetic parameters a linear three-compartment open model with elimination from the central compartment was used. With these parameters the drug concentrations in the peripheral compartments were simulated.
The final volume of distribution (3641 mL/kg) indicated drug accumulation inside cells, but equilibration between the body compartments was slow compared to drug elimination. The rate constants of distriubtion to the peripheral compartments (0.5 h and 0.3 h) were smaller than the elimination constant (0.9 h).
A reasonable correspondence between the expected concentrations in the small fast-exchanging compartment and the drug levels observed in erythrocytes was obtained. The large discrepancies during the first minues after infusion, when irregular changes of TRIS concentrations were found, may be due to a partial equilibration between plasma and erythrocytes in the time between drawing a blood sample and centrifuging it.
To evaluate a possible influence of the pH of the TRIS solution on drug distribution, the experiments with TRIS solution of pH 10.9 were repeated in the same animals. The results were the same as with TRIS solution of pH 7.4 (data of pH 10.9 not shown in the publication).
Inulin
A biexponential decline of inulin plasma levels was found in experiments with netural alkaline TRIS. A half-life of 42 min and a final volume of distribution of 275 mL/kg was calculated.
Metabolite characterisation studies
- Metabolites identified:
- not measured
Any other information on results incl. tables
The volume of the central compartment (223 mL/kg) was similar to the volume of the inulin space (data not given). Therefore the authors concluded that TRIS initially distributes to the extracellular space. The final volume of distribution of TRIS (3641 mL/kg) however, is much larger than the inulin space (275 mL/kg), which can only be explained by an accumulation of the drug inside cells.
Intracellular accumulation would be expected from the physicochemical properties of TRIS. Since the drug is a weak base with a pK-value of 7.92, 70% of the administered amount exists in the cationic form at normal plasma pH. Assuming that only the undissociated from can pass the cell membrance, the normal transmembrane pH-gradient may create a 2 -3 -fold higher intracellular drug concentration due to pH-partitioning. The observed drug levels in erythrocytes and the drug concentrations calculated for the peripheral compartments fit into this concept. In situations of elevated extracellular pH the accumulation of TRIS inside cells should be even greater. But the buffer capacity of plasma probably prevented a long-lasting rise of extracellular pH after infusion of TRIS solution of pH 10.9 and thus the results obtained with both solutions were identical.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): bioaccumulation potential cannot be judged based on study results
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.